Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-5 of 5 for your search:
Drug:
octreotide pamoate
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized, Double-Blind Study of 5-FU/SMS 201-995 pa LAR vs 5-FU/Placebo for Unresectable Stage II or Stage III/IV Pancreatic Cancer (Summary Last Modified 10/97)
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
SANDOZ-SMSM-304-E-00
, NCI-V95-0798
2.
Phase III Randomized Double-Blind Study of Tamoxifen/Octreotide Pamoate vs Tamoxifen/Placebo in Women with Locally Recurrent or Metastatic Breast Cancer (Summary Last Modified 12/98)
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
SANDOZ-SMST-302
, NCI-V96-0934
3.
Phase III Study of the Addition of Octreotide Pamoate (SMS 201-995 pa LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Women With Axillary Node Negative, Estrogen Receptor Positive, Primary Invasive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Completed
Age:
Not specified
Sponsor:
NCI
Protocol IDs:
NSABP-B-29
, NCT00002967
4.
Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CSMS995ADE05
, NCT00171873
5.
Phase I Study of Octreotide Pamoate With or Without Tamoxifen in Patients With Osteosarcoma (Summary Last Modified 12/2000)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
25 and under (at time of diagnosis)
Sponsor:
NCI
Protocol IDs:
NCI-95-C-0119I
, NCI-T96-0047N, T96-0047
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute